Mody SH - Search Results

1

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.

Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A. Sikand H, et al. Among authors: mody sh. Ann Pharmacother. 2008 Jan;42(1):16-23. doi: 10.1345/aph.1K061. Ann Pharmacother. 2008. PMID: 18029428

2

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.

Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT. Papatheofanis F, et al. Am J Ther. 2007 Jul-Aug;14(4):322-7. doi: 10.1097/MJT.0b013e31804bddec. Am J Ther. 2007. PMID: 17667204

3

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.

Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Papatheofanis FJ, et al. Among authors: mody sh. Curr Med Res Opin. 2006 May;22(5):837-42. doi: 10.1185/030079906X100113. Curr Med Res Opin. 2006. PMID: 16709305

4

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.

Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS. Lefebvre P, et al. Among authors: mody sh. Curr Med Res Opin. 2006 Sep;22(9):1623-31. doi: 10.1185/030079906X120968. Curr Med Res Opin. 2006. PMID: 16968565

5

The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.

Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT. Lefebvre P, et al. Among authors: mody sh. Dis Manag. 2007 Feb;10(1):37-45. doi: 10.1089/dis.2006.626. Dis Manag. 2007. PMID: 17309363

6

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.

Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS. Vekeman F, et al. Among authors: mody sh. Am J Health Syst Pharm. 2007 Sep 15;64(18):1943-9. doi: 10.2146/ajhp060585. Am J Health Syst Pharm. 2007. PMID: 17823106

7

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.

Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Duh MS, et al. Among authors: mody sh. Drugs Aging. 2006;23(12):969-76. doi: 10.2165/00002512-200623120-00004. Drugs Aging. 2006. PMID: 17154661

8

Daily cost of an intensive care unit day: the contribution of mechanical ventilation.

Dasta JF, McLaughlin TP, Mody SH, Piech CT. Dasta JF, et al. Among authors: mody sh. Crit Care Med. 2005 Jun;33(6):1266-71. doi: 10.1097/01.ccm.0000164543.14619.00. Crit Care Med. 2005. PMID: 15942342

9

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.

Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C. Duh MS, et al. Among authors: mody sh. Clin Ther. 2006 Sep;28(9):1443-50. doi: 10.1016/j.clinthera.2006.09.020. Clin Ther. 2006. PMID: 17062316

10

The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.

Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS. Moyneur E, et al. Among authors: mody sh. Dis Manag. 2008 Feb;11(1):49-58. doi: 10.1089/dis.2008.111715. Dis Manag. 2008. PMID: 18279115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters